These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 32322588)

  • 1. Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity.
    Schwach V; Slaats RH; Passier R
    Front Cardiovasc Med; 2020; 7():50. PubMed ID: 32322588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells.
    Nemade H; Chaudhari U; Acharya A; Hescheler J; Hengstler JG; Papadopoulos S; Sachinidis A
    Arch Toxicol; 2018 Apr; 92(4):1507-1524. PubMed ID: 29397400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity.
    Wu BB; Leung KT; Poon EN
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression Profiling of Human Pluripotent Stem Cell-Derived Cardiomyocytes Exposed to Doxorubicin-Integration and Visualization of Multi-Omics Data.
    Holmgren G; Sartipy P; Andersson CX; Lindahl A; Synnergren J
    Toxicol Sci; 2018 May; 163(1):182-195. PubMed ID: 29385562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling.
    Hsu WT; Huang CY; Yen CYT; Cheng AL; Hsieh PCH
    Theranostics; 2018; 8(12):3176-3188. PubMed ID: 29930721
    [No Abstract]   [Full Text] [Related]  

  • 6. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pluripotent Stem Cell Modeling of Anticancer Therapy-Induced Cardiotoxicity.
    Lyra-Leite DM; Burridge PW
    Curr Cardiol Rep; 2020 Jun; 22(8):56. PubMed ID: 32562096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
    Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
    Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs.
    Sachinidis A
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes.
    Maillet A; Tan K; Chai X; Sadananda SN; Mehta A; Ooi J; Hayden MR; Pouladi MA; Ghosh S; Shim W; Brunham LR
    Sci Rep; 2016 May; 6():25333. PubMed ID: 27142468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity.
    Liu S; Fang C; Zhong C; Li J; Xiao Q
    Cell Biol Toxicol; 2023 Dec; 39(6):2527-2549. PubMed ID: 37889357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4.
    Golforoush PA; Narasimhan P; Chaves-Guerrero PP; Lawrence E; Newton G; Yan R; Harding SE; Perrior T; Chapman KL; Schneider MD
    Sci Rep; 2020 Jul; 10(1):12060. PubMed ID: 32694738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
    Magdy T; Burmeister BT; Burridge PW
    Pharmacol Ther; 2016 Dec; 168():113-125. PubMed ID: 27609196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
    Ghigo A; Li M; Hirsch E
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative transcriptomics and cell systems analyses reveal protective pathways controlled by Igfbp-3 in anthracycline-induced cardiotoxicity.
    Chen J; Chapski DJ; Jong J; Awada J; Wang Y; Slamon DJ; Vondriska TM; Packard RRS
    FASEB J; 2023 Jun; 37(6):e22977. PubMed ID: 37219486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
    Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
    Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
    Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
    Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.